<DOC>
	<DOCNO>NCT00723957</DOCNO>
	<brief_summary>The purpose study determine whether progression-free survival ixabepilone superior achieve paclitaxel plus carboplatin participant advance nonsmall-cell lung cancer beta III ( βIII ) -tubulin-positive tumor .</brief_summary>
	<brief_title>A Randomized Phase 2 Study Ixabepilone Plus Carboplatin Paclitaxel Plus Carboplatin Advanced Nonsmall-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer ( NSCLC ) ( squamous cell , adenocarcinoma , large cell , bronchoalveolar carcinoma ) Stage IIIB NSCLC pleural effusion , Stage IV NSCLC , recurrent disease follow surgery without radiation therapy Available paraffinembedded tissue measure expression level βIII tubulin Disease measurable Response Evaluation Criteria Solid Tumors , least 1 target lesion situate outside previous radiotherapy field Karnofsky performance status 70100 Life expectancy least 3 month Men woman , age 18 year old Uncontrolled brain metastasis Peripheral neuropathy great Grade 1 Fewer 4 week prior radiation therapy locoregional surgery randomization date ( le 1 week focal/palliative radiotherapy minor surgery ) Any concurrent malignancy nonmelanoma skin cancer carcinoma situ cervix Known HIVpositive status Absolute neutrophil count lower 1500 cell mm^3 Total bilirubin level high upper limit normal ( ULN ) define institution ( exception elevation due Gilbert 's syndrome ) Aspartate transaminase alanine transaminase level high 2.5*ULN Serum creatine level 1.5 mg/dL high Renal function creatinine clearance le 50 mL/min ( calculate Cockcroft Gault equation ) Any prior antineoplastic systemic regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>